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EXECUTIVE SUMMARY 
 
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disease affecting 
approximately 7 million people globally with devastating socioeconomic effects on 
individuals, their families and society. Total European costs of PD in 2010 alone accounted for 
€13.9 billion. Worryingly the global prevalence of PD is increasing over time and it is expected 
to double within the next 20 years (up to 2% in people over the age of 60 and 6% in people 
over 80 years). Targeting unmet needs in the management of PD is crucial for addressing 
the growing socioeconomic burden of the disease and to ensure sustainability in the 
treatment of this chronic condition. The objective of this report is to summarise the key 
evidence available from the literature on the potential clinical and socioeconomic impact of 
targeting unmet needs in PD.   
MISSED OR MISDIAGNOSIS AND DELAYS IN TREATMENT. There is no diagnostically 
conclusive test for PD yet, so the diagnosis is clinical in nature. In the clinical setting, PD is 
commonly missed or misdiagnosed since many symptoms of PD are also common to other 
diseases both neurodegenerative and non-neurodegenerative. The diagnosis and treatment 
of PD typically occurs when the disease has already progressed to a relatively advanced stage 
in which motor symptoms are clearly evident and substantial neurophysiological damage has 
already taken place. At this point, any possibility of delaying disease progression or, achieving 
neuroprotection may already be out of reach.  
 New developments in early diagnosis and treatment. A revised definition of PD, together 
with the availability of novel diagnostic tools can allow for earlier diagnosis, and therefore 
treatment. Non-motor symptoms, which account for a large proportion of PD symptoms 
and usually emerge much earlier, are increasingly recognized as useful indicators to 
achieve earlier diagnosis. Furthermore, a number of new and diverse diagnostic tools (i.e. 
biological and genetic biomarkers, imaging techniques) are now available and have the 
potential to make earlier diagnosis, and consequently earlier treatment, possible.  
 The benefits of early diagnosis and treatment. A growing body of evidence from the 
medical literature describes numerous advantages that may be associated with early 
therapeutic intervention in PD. The most evident benefit of early treatment with 
medicines other than L-dopa is the reduction in symptoms (for example difficulty or 
distortion in performing voluntary movements) and the delay of levodopa (L-dopa) 
initiation and therefore its immediate side-effects (for example hypotension, arrhythmia, 
insomnia and hallucinations) and the effects of its chronic administration (motor 
complications and drug resistance). Clinical trials also suggest that early treatment can 
slow disease progression.  
Both the decrease of symptoms and the potential for slowing disease progression, have a 
major impact on improving patient quality of life (QoL) and reducing the costs associated 
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with PD in the long run, as the great majority of costs attributable to PD occur when the 
disease is at its most advanced stage and when symptoms are most severe.  
 
Despite this apparent benefit of utilizing dopamine agonists in early PD to delay the need 
for L-dopa and to achieve cost savings, there is still controversy regarding when to 
initiate treatment. If with early treatment we consider the disease being treated soon 
after standard PD diagnosis has been achieved there is economic evidence to 
demonstrate that treatments (other than L-dopa) can be cost-effective. If early PD is 
defined as that period prior to the onset of significant motor symptoms, then, as 
considered with clinical outcomes, few data are available on the real potential for cost 
savings. 
NON-ADHERENCE. Non-adherence is common, critical, and costly in PD. It presents serious 
socio-economic consequences and well-being deterioration not only for the patients but also 
for family members. PD patients in general have poor adherence to prescribed therapies, 
especially therapies with complex dosing schedules.  
 The benefit of more convenient and adherence-friendly drug formulations, regimen 
simplification, mailed and telephoned reminders or reinforcement, counselling, and 
supportive care may further help to improve outcomes and lower costs in PD. 
 A series of studies in the USA reported that increased medication adherence can result in 
significant savings in direct costs related to hospitalisations, visits and medicines. 
FUTURE RESEARCH DEVELOPMENTS 
 Rethinking what PD is and how/when it can be diagnosed. The recent developments in 
PD diagnosis emphasise the necessity of rethinking what PD is and how, and when, it can 
be diagnosed. Clinicians are aware that the current diagnostic tools and guidance should 
be updated in light of current knowledge of PD to optimize its early detection. 
 If early PD is defined as that period prior to the onset of significant motor symptoms, 
before substantial neurological damage may have occurred, then more research would 
be needed to explore the real impact of early treatment both on clinical and economic 
outcomes.  
 The benefit of alternative approaches (such as integrated care models) should be further 
explored as opportunities to improve outcomes and lower costs in PD. The EBC Value of 
Treatment project for 2015-2017 aims at developing and applying to brain disorders a 
new integrated care model framework and therefore promote a more holistic 
management of chronic conditions in Europe. The project will provide policy 
recommendations on how to implement effective and cost-effective interventions for 
brain disorders across different European health systems and specific case studies, 
including Parkinson’s disease.  
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1. PARKINSON’S DISEASE (PD), ITS MANAGEMENT AND 
SOCIOECONOMIC IMPACT 
 
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder that causes 
significant disability and reduces quality of life (QoL), with significant impact on costs to the 
healthcare system and society as a whole.  
1.1. NEUROPATHOLOGY AND SYNTOMS 
The two major findings when studying the nervous system tissue of individuals with Parkinson 
disease are loss of neuronal cell and the presence of Lewy bodies (abnormal aggregates of 
protein that develop inside nerve cells) in the mid brain (substantia nigra, that plays an 
important role in reward, addiction, and movement). 1,2 Both the cause and cure for PD are 
yet unknown. PD's symptoms are caused by a decrease in the levels of the chemical 
messenger dopamine, which allows messages to be sent to the parts of the brain that co-
ordinate movement, due to the death of dopamine-producing nerve cells. With the loss of 
dopamine-producing nerve cells, these parts of the brain are unable to function normally, 
causing the symptoms of PD's to appear. These symptoms include tremor, slowed movement, 
rigid muscles, impaired posture and balance, loss of automatic movements, along with 
changes in speech and writing (see below).  
1.2. EPIDEMIOLOGY 
The European Brain Council (EBC) published a study on brain disorders and their epidemiology 
in 2005.3 There are around 466 million people in Europe, 127 million (27%) of whom have 
brain disorders (both neurological and general mental health). If those with co-morbidities 
are excluded, that still leaves 104 million people (22%), roughly half of whom (51.2 million 
people; 11%) have a neurological condition. The number with PD is estimated to be around 
1.1 million (0.2%).4 In 2010 the overall European estimates increased this number to 1.25 
million cases of PD5. 
PD is the second most common neurodegenerative disorder after Alzheimer’s disease (6) 
affecting approximately 7 million people globally and is a major and increasing burden on 
patients, families, carers and healthcare systems.7 A recent meta-analysis of the worldwide 
data showed a rising prevalence of PD with age (all per 100,000): 41 in 40 to 49 years; 107 in 
50 to 59 years; 173 in 55 to 64 years; 428 in 60 to 69 years; 425 in 65 to 74 years; 1087 in 70 
to 79 years; and 1903 in older than age 80.8 
The prevalence of PD in industrialised countries, although the exact prevalence is difficult to 
accurately determine, is thought to be approximately 0.3%.9 This rises to 1% in people over 
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the age of 60 and 3% in people over 80 years.6  Country specific evidence is reported 
elsewhere (UK10, Spain11, USA12 international comparison13). 
 
Due to the ageing of the population, with a greater proportion of the population aged 65 and 
older, and due to the positive correlation between prevalence and age, PD is likely to become 
more prevalent in the next years and is expected to double within the next 20 years . The rise 
in prevalence brings substantial concerns with respect to the growing socioeconomic burden 
and sustainability of this chronic condition.  
1.3. SOCIAL AND ECONOMIC COSTS, AND QUALITY OF LIFE 
Cost of illness escalates as PD progresses, placing an economic burden on the healthcare 
system, society and patients themselves. According to the EBC data for 2004, annual spend in 
Europe on PD was €10.7 billion, consisting of €4.6 billion on healthcare costs and €6.1 billion 
on direct non-medical costs. This is more than 12% of the total spend on neurological diseases 
in Europe, which was €83.9 billion. In 2010 the total European cost of PD increased to €13.9 
billion (30% more compared with previous estimates in 2004)5. DALY estimates (age15+) for 
the EU-27 population in 2010 is 174,0378.14  In USA Kowal and colleagues15 showed that the 
national economic burden of PD exceeds US$14.4 billion [€12.2 billion]  in 2010 
(approximately US$22,800 [€20,296] per patient). The population with PD incurred medical 
expenses of approximately US$14 billion [€12 billion] in 2010, US$8.1 billion [€7.21 billion] 
higher (US$12,800 [€11,393] per capita) than expected for a similar population without PD. 
Indirect costs (e.g., reduced employment) are conservatively estimated at US$6.3 billion [€5.6 
billion] (or close to US$10,000 [€8,901] per person with PD).  
Despite the progressive decline and comorbidity associated with PD, the lifespan of affected 
individuals, treated with innovative drug therapy, does not differ greatly from age matched 
individuals without PD.16 As a result, people may live up to 20 or more years with PD. This 
finding has serious implications for the cost of treating PD over the individual’s lifetime and 
suggests that the financial burden will escalate over time. In addition, the economic burden 
is likely to increase further as the proportion of individuals in Western societies aged over 65 
increases.17 
 
PD does not directly cause people to die and for the majority of people does not significantly 
affect their life expectancy even though some of the more advanced symptoms can lead to 
increased disability and poor health, which can make someone more vulnerable to infection. 
Despite little impact on life expectancy, PD patients experience progressive disability and 
reduced QoL at all stages of the disease and at all ages. Several studies indicate that QoL is 
affected not only by the motor symptoms of PD, but also by the pre-motor symptoms such as 
depression and cognitive state (for examples see 18,19,20).  
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 Impairments in motor function such as tremor, slowed movements, loss of voluntary 
movements, muscular rigidity and postural instability cause problems with mobility 
and interfere with activities of daily living. Problems with balance and gait (rhythmic 
stepping movements for travel) can lead to falls and injuries, and the inability to 
perform everyday tasks. Other symptoms include poor hand co-ordination, problems 
with handwriting, and a sensation of tremor (shaking) in the arm.  
 
 Early PD's symptoms often include pre-motor symptoms such as depression, 
dementia, feeling tired and weak, reduced ability to smell and to detect odours, acting 
out vivid dreams during sleep (REM sleep behaviour disorder), along with problems 
with blood pressure, heart rate, sweating, and digestion of food. Visual symptoms 
often precede the clinical diagnosis and increase over time.12 Symptoms vary greatly 
from person to person and can sometimes take years to progress to a point where 
they cause problems.  
 
2. UNMET NEEDS  
1.4. MISSED OR MISDIAGNOSIS 
PD is challenging to diagnose, since there are no well-established biomarkers to determine if 
the disease is present.21 There is no diagnostically conclusive test for PD, so the diagnosis is 
clinical in nature and is made by identification of slowness of movements (bradykinesia) and 
at least one of the following symptoms: resting tremor, muscle rigidity, and postural 
instability.22 Confirmation of a PD diagnosis also involves exclusion of other disease and 
presence of at least three positive criteria, which include: affecting one side of the body, 
shaking of the limb when the person is at rest (resting tremor), progressive disorder, 
persistent asymmetry affecting side of onset most prominently, excellent response to 
levodopa (L-dopa), severe involuntary movements affecting especially the shoulders, hips, 
and face induced by L-dopa, L-dopa response for 5 years or more, or clinical course of 10 years 
or more.22,23 Current diagnostic modalities in PD are limited by the fact that they identify 
PD by the presence of motor symptoms; by this point, around 70% of all dopamine neurons 
may have been lost24. Thus, the diagnosis of PD remains a challenge for clinicians, 
particularly in the pre-clinical, or early phase, before the motor symptoms appear. Despite 
pre-motor symptoms preceding the clinical diagnosis, none of these are sufficiently specific 
to be used as stand-alone biomarkers, thereby preventing the achievement of an early 
diagnosis.  
 
PD, in the clinical setting, is commonly missed or misdiagnosed. Many symptoms of PD are 
also common to a range of conditions, and this may cause missed or misdiagnosis of PD. These 
4 
 
conditions can be grouped as neurodegenerative, which primarily affect the neurons in the 
human brain, non-neurodegenerative, which do not affect the human brain. Among the 
neurodegenerative diseases, those most often confused with PD are multiple system atrophy 
(MSA; this cell degeneration causes problems with movement, balance, and autonomic 
functions of the body such as bladder control or blood-pressure regulation), progressive 
supranuclear palsy (PSP; uncommon brain disorder that affects movement, control of walking 
(gait) and balance, speech, swallowing, vision, mood and behaviour, and thinking), 
corticobasal degeneration (CBD; it is a rare condition that can cause gradually worsening 
problems with movement, speech, memory and swallowing), dementia with Lewy bodies 
(DLB; it is a type of progressive dementia that leads to a decline in thinking, reasoning and 
independent function because of abnormal microscopic deposits that damage brain cells over 
time), normal pressure hydrocephalus (NPH; is an accumulation of fluid in the brain that 
causes the ventricles in the brain to become enlarged), and Alzheimer’s disease (AD; it implies 
a progressive mental deterioration associated with gradual death of brain cells).25,26 Essential 
tremor (ET; that is a type of uncontrollable shake or tremble of part of the body) is also a 
common source of confusion in PD diagnosis, although many of these patients will go on to 
develop PD.27 Furthermore people can develop DP symptoms following treatment with 
particular medications (drug-induced Parkinsonism); this form is very common and may 
constitute the second-most common cause of Parkinsonism.28  
 
The probability of misdiagnosis appears to be strongly related to whom is doing the 
diagnosing and whether or not the clinician is applying diagnostic criteria from clinical 
guidelines, although application of the clinical criteria is not a guarantee of diagnostic 
accuracy. There is evidence showing that nearly half (47%) of PD diagnoses are incorrect when 
performed in the primary care setting, and specialists whose expertise is not specific 
movement disorders have an error rate of approximately 25%, while movement disorder 
specialists are mistaken in only 6% to 8% of cases.10 
1.5. NON-TREATMENT 
Since there is currently no cure for PD, the main treatment goal is to manage the symptoms 
and there are several medicines available for the management of its symptoms. Although 
medicines can improve QoL29, there is a significant decline in physical mobility, pain, social 
isolation and emotional reactions as the disease progresses.25 Patients with PD who remain 
untreated, or inappropriately treated, will experience ongoing and substantial symptomatic 
deterioration and negative effects on their QoL.30  In a recent survey 1,400 patients with 
essential tremor (including PD) identified a broad range of unmet needs that they felt were 
not addressed in their treatment31.  The most reported issues related to what they felt was 
inappropriate treatment included:  
 Lack of psychological services and support (33.9%);  
 Lack of physical or occupational therapy (28.6%);  
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 Lack of support in handling embarrassment and social effects of tremor (15.8%);  
 Feelings of not being in control (13.7%);  
 Lack of detailed report and a more quantitative way of assessing tremor and tracking 
progression (12.7%); 
 Lack of information about current treatment and medications (11.9%);  
 Lack of empathy, compassion and a feeling of being heard (11.6%),  
 Lack of alternative treatment approaches other than just medications and surgery 
(11.2%); 
 Lack of discussion of all symptoms aside from tremor (e.g., cognition, balance; less 
than 10%).  
1.6. NON-ADHERENCE  
Medication non-adherence is prevalent in Parkinson's disease (PD) and results in substantial 
motor dysfunction. Leopold and colleagues (2004)32 showed that only 10% of PD patients fully 
adhered to treatment. A further study identified that 20% of patients with PD were under 
users of anti-parkinsonian medication.33 In addition, patients who satisfactorily adhered to 
medication (average total pill taking > 80%) all showed substantial problems with dose timing 
adherence (number of doses taken at the correct time interval). Kulkarni and colleagues 
(2008) conducted a retrospective longitudinal cohort study in people with PD and found the 
prevalence of sub-optimal adherence to be 67%.34  
Medication non-adherence is therefore a significant problem in people with PD and it can be 
related to several factors, including35: 
 Polypharmacy is very common with over half of patients taking at least two anti-
parkinsonian medicines in addition to multiple prescriptions for non-motor 
manifestations and other comorbidities. Furthermore, dopaminergic medicines are 
often taken 3–4 times daily, with advanced PD patients taking as many as 6–10 doses 
per day. Greater regimen complexity is strongly correlated with non-adherence in 
PD.36,37  
 
 Depression and mood disorders have been identified as an independent risk factor for 
non-adherence and a common non-motor manifestation of PD. Studies in depressed 
populations have found a threefold increase in non-adherence with all prescribed 
medications38 and a single-centre study found non-adherence was associated with 
worse depression and poorer quality of life in PD.39 
 
 Deficits in the management (regulation, control) of cognitive processes, including 
working memory, reasoning, flexibility, and problem solving as well as planning and 
execution is another common feature of PD and contributor to non-adherence. These 
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deficits are common in PD and have been independently associated with medication 
non-adherence.40  
 
 Additional factors associated with non-adherence include poor quality of life and 
symptoms control, poor knowledge of PD, lack of social support/partner39, non-
modifiable demographic and educational factors41 low health literacy42, low income, 
maintaining employment, and the cost of medications.43  
Consequences of non-adherence include worse disease control, with diminished mobility, 
greater movement problems, involuntary muscle movements, diminished voluntary 
movements and worsening quality of life. Non-adherent individuals are more likely to report 
being undertreated, rather than recognising that their sub optimally controlled symptoms 
may be caused by their non-adherence to treatment. Similarly the healthcare provider may 
react increasing the medication doses or frequencies, changing the medicine regimens, or 
questioning the diagnosis, leading to additional diagnostic testing, patient stress, and further 
non-adherence.44 
1.7. WHY EARLY INTERVENTION AND ADHERENCE ARE IMPORTANT IN PD?  
1.7.1 EARLY INTERVENTION 
There is growing evidence that early intervention may help in preserving the functioning of 
the neurons, reducing symptoms, particularly difficulty or distortion in performing voluntary 
movements, slowing disease progression, improving patient QoL and, in turn, reducing the 
overall costs associated with PD45. However early treatment relies on early diagnosis and, as 
already pointed out, early diagnosis and treatment of PD can be difficult to achieve because 
the nature of diagnosis (mostly clinical). Therefore by the time motor symptoms emerge, 
significant neurological damage and the destructive structural changes have already taken 
place. PD diagnosis by conventional means identifies a disease which is already advanced, and 
any possibility of delaying disease progression, not to mention neuroprotection, may already 
be out of reach. Despite the fact that diagnosis remains mainly clinical, recently, the 
increasing recognition of pre-motor symptoms together with a number of new and diverse 
techniques for diagnosis have the potential to considerably alter the diagnostic landscape in 
the next future, making the early diagnosis, and therefore treatment, achievable.46  
1.7.2 ADHERENCE  
Poor treatment adherence is a significant challenge to optimizing outcomes in PD, and any 
therapeutic strategy must take into consideration those factors impacting treatment 
adherence.  
In PD pharmacological management is essential for managing symptoms and maximising QoL; 
therefore medication adherence is paramount to securing effective treatment.47 This is 
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especially relevant as motor function becomes progressively worse, requiring increasingly 
intricate medication regimes to manage symptoms.48 Furthermore, as non-motor symptoms 
have been reported by patients and carers to be more negatively impactful than motor 
complaints in PD49,50, adequately adhering to prescribed regimens is likely to be important for 
maximising health related QoL.  
Fargel et al surveyed 500 patients with PD and 592 neurologists who treated patients with 
PD, in order to determine the causes of poor adherence.51 The authors found that while 
physicians described themselves as being satisfied with the “pill load” of prescribed 
medications for their patients, the PD patients themselves were largely dissatisfied and 
wished for simpler medicine regimens as follow:  
 A reduction in daily tablet intake was the most common request for treatment 
improvement; 
 Moreover, patients expressed their preferences for alternative delivery systems, 
most of all transdermal patches, to facilitate the ease of delivery of their PD treatment 
(and this was reported also by the neurologists).  
These results are consistent with a recently international study (2014) comparing patient 
preference for pramipexole in once daily versus 3-times-daily formulations in patients with 
either early or advanced PD; the majority of the patients (94.4%) reported their preference 
for the once-daily formulation.52 In another from Spain (2012) it was reported as follow:  
 Strong correlation between treatment adherence to L-dopa and the total number of 
daily medicines (as opposed to pills) prescribed;  
 Poorer adherence associated with higher L-dopa doses;  
 Higher rates of adherence in patients who were treated first with a dopamine agonist 
versus those first treated with L-dopa.53  
A transdermal patch of the dopamine agonist rotigotine, which has shown safety and efficacy 
in early PD and non-inferiority to pramipexole, was recently approved for PD treatment by 
the FDA, and offers a therapy that is likely to be associated with higher rates of adherence 
compared with oral therapies.54  
3. WHAT INFORMATION IS AVAILABLE IN THE LITERATURE ABOUT 
EARLY DIAGNOSIS AND TREATMENT?  
3.1. DIAGNOSTIC TOOLS AVAILABLE TO ACHIEVE EARLIER DIAGNOSIS 
Among the diagnostic tools which might help in achieving earlier diagnosis there are: non-
motor (or pre-motor) symptoms, biomarkers (biological and genetic) and neuroimaging 
techniques. 
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3.1.1. NON-MOTOR (OR PRE-MOTOR) SYMPTOMS 
Although motor symptoms are the most recognizable of symptoms in PD, and are those upon 
which a PD diagnosis is largely based on, non-motor symptoms represent not only a large 
proportion of overall PD symptoms but, in many cases, emerge earlier than motor 
symptoms. The non-motor symptoms could be present for up to 10 years before the diagnosis 
is made and have been shown to exert a greater negative influence on QoL than motor 
symptoms.55,56 Thus, despite the fact that the standard diagnosis of PD still relies on motor 
symptoms, pre-motor symptoms hold promise for the early diagnosis of PD, and considerable 
progress has been made in recent years in establishing pre-motor symptoms as a means of 
identifying PD much earlier than in the past. One important observation is that PD is not 
simply a central nervous system (CNS) disease in which the peripheral nervous system (PNS) 
plays a minor part. Rather, PNS seems to play a much larger role than previously assumed, 
particularly in the early stages of the disease.57 Many of the pre-motor symptoms that arise 
in early PD emerge in PNS structures, and there is compelling evidence suggesting that PD 
actually begins in the PNS.58,59 
 
The manifestations of pre-motor symptoms in PD are diverse, affecting sensing smell, 
gastrointestinal and urinary function, mood and sleep, as well as a variety of cerebral activities 
(reasoning, memory, attention, and language and lead directly to the attainment of 
information and, thus, knowledge).  
 
 Dysfunctions of the stomach and the intestines that manifest as pre-motor symptoms 
include gastroparesis (a disorder that slows or stops the movement of food from the 
stomach to the small intestine) and constipation (bowel movements are difficult or 
happen less often than normal). In this regard, the presence of Lewy bodies in the 
gastrointestinal tract may provide a means for early diagnosis of PD.60  
 Urinary dysfunctions- Urinary frequency, urgency, and nocturia (condition in which 
you wake up during the night because you have to urinate) constitute urinary 
dysfunctions in early PD.  
 Sexual dysfunction in both men (erectile and ejaculation dysfunction) and women 
(poor vaginal lubrication and difficulty achieving orgasm) have also been observed as 
PD pre-motor symptoms.  
 Mood disorders, including depression and anxiety, are well documented in the pre-
motor phase, while sleep disturbances, including REM behaviour disorder (acting out 
vivid dreams as they sleep) and excessive daytime sleepiness, are common premotor 
symptoms.  
 Other non-motor PD symptoms that may play a role in the premotor phase include 
pain, apathy (lack of feeling), attention/memory problems, restless legs syndrome 
(RLS; it is a neurological disorder characterized by an irresistible urge to move one's 
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body to stop uncomfortable or odd sensations), fatigue, and poor ability to 
discriminate colours.59 
 Hyposmia (reduced ability to smell and to detect odours),61 may be the most notable 
of non-motor symptoms observed in the pre-motor stage, in part because of the 
growing quantity of data demonstrating and explicating the role of smell loss in PD, 
but also because it may represent a highly useful means of achieving diagnosis of PD 
much earlier than has been possible up until the present.57 The results of several 
studies investigating the smell function in PD have been encouraging in considering 
smell testing as a means of early PD detection either alone62-64 or in combination with 
neuroimaging techniques.64,65 However, hyposmia is also associated with other 
conditions, including Alzheimer’s disease and dementia with Lewy bodies, and thus 
the presence of hyposmia may be useful for the identification of persons at risk for 
PD, rather than being conclusively diagnostic of PD.66  
3.1.2. BIOLOGICAL AND GENETIC BIOMARKERS 
Several different biological indicators (biomarkers) in body fluids such as the brain and spine 
fluid (cerebrospinal fluid; CSF) as well as the blood and urine, have been proposed for use in 
the diagnosis of PD. Challenges to the use of biomarkers revolve around the fact that changes 
over the course of the disease can affect their measurable levels, and even their presence. 
Moreover, the manifestations of biomarkers in other diseases characterised by reduction or 
impairment of cognitive function may be too similar to those seen in PD to allow them to be 
easily identified.21 It is common understanding that a combination of several biomarkers 
will be required to achieve reliable early PD diagnosis.67 In addition to biological biomarkers, 
recent research into genetic biomarkers for early PD have also shown promising results.68,69  
3.1.3. NEUROIMAGING TECHNIQUES  
Several neuroimaging approaches (various techniques to either directly or indirectly image 
the structure, function/pharmacology of the nervous system) have demonstrated viability in 
the detection of PD and are therefore used as an additional tool in the examination of the 
brain in order to make a diagnosis of brain diseases.  A few neuroimaging techniques are 
currently available and they include single photon emission computed tomography (SPECT), 
transcranial sonography (TCS), positron emission tomography (PET), magnetic resonance 
imaging (MRI).70 Unfortunately, they have significant limitations: 
 
 SPECT is more accessible to clinicians than PET and less expensive; however it cannot 
differentiate PD from other disorders such as multisystem atrophy (MSA; it is 
associated with the degeneration of nerve cells in specific areas of the brain and can  
leads to premature death), progressive supranuclear palsy (PSP; a rare and 
progressive condition that can cause problems with balance, speech, swallowing, 
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vision, mood and behaviour, and thinking), and corticobasal degeneration (CBD; it is 
a rare condition that can cause gradually worsening problems with movement, 
speech, memory and swallowing).  
 TCS is also more accessible and less expensive than PET and it has been proven to be 
a useful technique in the diagnosis and differential diagnosis of movement disorders.21  
 MRI provides excellent resolution and diagnostic sensitivity and can facilitate the 
diagnosis of neurodegenerative conditions. Structural imaging with MRI is an 
alternative to SPECT, TCS and PET and particularly for patients with clinical features 
that are atypical for PD; however its utility as a diagnostic tool is not widely accepted.71 
 
In vivo magnetic resonance spectroscopy (MRS) is an additional tool that can be used to 
complement the more common MRI in the characterization of tissue. MRS can provide a 
useful and objective tool for detection of metabolic changes of the brain in patients with PD 
and has been shown to meet many of the criteria of an ideal imaging biomarker. Indeed, MRS 
has good consistency (test-retest reliability) and, compared with PET and SPECT, is non-
invasive and cheap, and it does not require contrast agents for the molecular imaging 
reducing exposure to radioactive substances. In addition, compared with some in vitro 
molecular biomarkers that require a complex analysis, MRS is not restricted to specialized 
centres to perform the analysis, making its extension to general public health centres 
possible. The recent technical advances of MRS allowed achieving in vivo detailed information 
on pathophysiology of PD. Several studies demonstrated the usefulness of MRS to achieve 
a differential diagnosis of PD versus other forms of Parkinsonism, especially in early stages 
of disease in which signs and symptoms of different forms of Parkinsonism have greater 
overlap.  
 
All these neuroimaging techniques, in addition to offering a valuable tool to make earlier 
diagnosis of PD, could be also used to monitor disease progression. However, the utility of 
these modalities as biomarkers for evaluating the efficacy of therapeutic interventions to slow 
disease progression remains imperfect, and additional investigations are needed before being 
able to introduce them into clinical practice.45  
 
3.2. THE CLINICAL BENEFITS OF EARLY INTERVENTION 
Several studies have been undertaken to assess the clinical benefit of early treatment of PD 
with levodopa (L-dopa)72,73, dopamine agonists74-78 and Monoamine Oxidase Type-B (MAO-
B) inhibitors79-84 (Table). The majority of the studies evaluating the benefit of early treatment 
refer to studies investigating the clinical efficacy of a PD medicine (i.e. L-dopa or dopamine 
agonist or MAO-B inhibitor) in the early stages of the disease without directly comparing early 
vs. delayed treatment.72-81  Only a few studies allow for such a comparison.82-84 Details on the 
different studies are reported in the table below.  
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Table. Main studies of clinical benefit of early treatment of PD  
Study Type of study Publication 
year 
Intervention Comparator N Follow-up Main outcome 
L-dopa 
ELLDOPA72  Clinical trial 2004 Carbidopa-L-dopa 
at various doses 
Matched placebo 361 42 weeks L-dopa improved UPDRS score* 
in a dose-related fashion 
SPECT [123I] 
β-CIT uptake 
sub-study72 
Clinical Trial 2004 Carbidopa-L-dopa 
at various doses 
Matched placebo 116 42 weeks SPECT demonstrated that L-
dopa accelerates the loss of 
nigrostriatal dopamine nerve 
terminals 
STRIDE-PD73 Clinical Trial 2010 Carbidopa-L-dopa 
plus entacapone 
Carbidopa-L-dopa 747 134 weeks Intervention group had shorter 
time to dyskinesia onset and 
increased frequency of dyskinesia 
Dopamine agonists 
Rascol et al74 Clinical Trial 2000 Ropinirole Benserazide-L-
dopa 
268 5 years Intervention had longer time to 
dyskinesia; no significant 
difference in the mean change in 
UPDRS activities of daily living 
subscale scores between the two 
groups 
CALM-PD-CIT 
77 
Clinical Trial 2002 Pramipexole Carbidopa-L-dopa 82 46 months SPECT showed less 
dopamine neuron degeneration 
with pramipexole; UPDRS scores 
similar in both groups 
REAL-PET75 Clinical Trial 2003 Ropinirole Carbidopa-L-dopa 186 2 years PET showed slower disease 
progression with ropinirole. 
However, better UPDRS motor 
score improvement with L-dopa. 
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Study Type of study Publication 
year 
Intervention Comparator N Follow-up Main outcome 
CALM-PD76 Clinical Trial 2005 Pramipexole Placebo-L-dopa 
or carbidopa-L-
dopa 
301 48 months Reduction in dyskinesia and 
wearing-off with pramipexole, 
but better total score and motor 
score and  lower incidences of 
side effect (i.e. freezing, 
somnolence, and edema) in the 
L-dopa group 
Stowe et al78 Meta-
analysis 
2008 Dopamine 
agonists 
L-dopa 5247 n.a. Less motor complications (i.e. 
dyskinesia, dystonia) 
with dopamine 
agonists compared to L-dopa, but 
more side-effects and poorer 
symptom control 
PD MED trial85 Clinical Trial 2014 L-dopa dopamine 
agonists (DA) and 
monoamine 
oxidase type B 
inhibitors 
(MAOBI) 
1620 36 months L-dopa provides better mobility 
and a higher quality of life than 
the two main alternatives, 
dopamine agonists (DA) and 
monoamine oxidase type B 
inhibitors (MAOBI) 
MAO-B inhibitors 
DATATOP80 Clinical Trial 1993 Selegiline and/or 
tocopherol 
Placebo 800 24 months Selegiline delayed the onset 
of disability requiring L-dopa 
therapy and the decline in UPDRS 
total score compared with 
placebo or tocopherol 
TEMPO81  Clinical Trial 2002 Rasagiline Placebo 404 26 weeks Rasagiline improved UPDRS 
scores; no difference in the 
frequency of adverse events 
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Study Type of study Publication 
year 
Intervention Comparator N Follow-up Main outcome 
Ives et al79 Meta-
analysis 
2008 MAO-B inhibitor Placebo or L-dopa 3525 n.a. Better total UPDRS scores, UPDRS 
motor scores and activities of 
daily living scores with MAO-B 
inhibitor 
ADAGIO82 Clinical Trial 2009 Rasagiline 1 mg or 
2 mg daily for 72 
weeks 
Placebo for the 
first 36 weeks, 
then rasagiline 1 
mg or 2 mg daily 
for the remaining 
36 weeks 
1176 72 weeks Improved UPDRS scores in the 
early-start group compared to 
delayed-start group, with 
rasagiline 1 mg but not with 2 mg 
dosage 
Hauser et al84 6.5-year 
extension of 
the TEMPO 
study 
2009 Rasagiline (early-
start group) 
Placebo for 6 
months followed 
by rasagiline 
(delayed-start 
group) 
306 6.5 years Less worsening in total UPDRS 
scores in the early-start 
group compared to delayed-star 
group 
Rascol et al83 prespecified 
and post-hoc 
analyses of 
the ADAGIO 
study 
2011 See Adagio study82 UPDRS motor subscores and 
activities of daily living subscale 
improved with both doses of 
rasagiline relative to placebo in 
the early-start versus the 
delayed-start groups 
The unified Parkinson's disease rating scale (UPDRS) is used to follow the longitudinal course of PD. It is made up of the 1) Mentation, 
Behaviour, and Mood, 2) ADL and 3) Motor sections. These are evaluated by interview. Some sections require multiple grades assigned to each 
extremity. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability. Single photon emission computed 
tomography (SPECT), positron emission tomography (PET).
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3.2.1. LEVODOPA (L-DOPA)-BASED REGIMENS 
L-dopa is the standard therapy for motor control of PD and it is still considered the most 
effective drug for relieving the widest range of symptoms, including: tremor, stiffness, 
slowness, poor muscle control, balance, and difficulties in walking.  
In one of the first studies Parkinson’s Study Group examined carbidopa-L-dopa at various daily 
doses (compared with placebo; Earlier versus Later L-dopa Therapy in PD; ELLDOPA trial); the 
clinical data suggested that L-dopa either slows the progression of PD or has a prolonged 
effect on its symptoms. In contrast, the neuroimaging data suggested either that L-dopa 
accelerates the loss of nerve terminals or that its pharmacologic effects modify the dopamine 
transporter.  
The potential long-term effects of L-dopa on PD remain uncertain.72 Although L-dopa is the 
most widely used (and effective) therapy for PD, chronic treatment is associated with motor 
complications in the majority of patients. It has been hypothesized that providing more 
continuous delivery of L-dopa to the brain would reduce the risk of motor complications, and 
that this might be accomplished by combining L-dopa with entacapone to extend its 
metabolisim. The STRIDE-PD trial, comparing carbidopa-L-dopa with or without entacapone, 
showed that initiating L-dopa therapy with L-dopa/carbidopa/entacapone (LCE) failed to 
delay the time of onset or reduce the frequency of dyskinesia compared to L-dopa/carbidopa 
(LC). In fact, LCE was associated with a shorter time to onset and increased frequency of 
dyskinesia compared to LC.  In addition they found no difference in longitudinal course of PD 
between the groups, but the incidence of myocardial infarction was 1.9% in the LCE group 
versus 0% in the LC group, concluding that the addition of entacapone to carbidopa-L-dopa 
may actually be deleterious with the increased risk of myocardial infarction.73  
3.2.2. DOPAMINE AGONISTS 
Because L-dopa controls the symptoms of PD so well (and with so few side effects at the 
beginning) there is some benefit for people who start treatment with L-dopa, rather than with 
a dopamine agonist. A person with PD who starts treatment with L-dopa may have more early 
years with better control of symptoms and fewer side effects. But it also is well documented 
that most people who take L-dopa develop motor problems (motor fluctuations or wearing-
off) within 5 to 10 years after starting the medicine. These complications, including 
unpredictable swings in motor control between doses and uncontrollable jerking or twitching 
(dyskinesias), can be hard to manage and can become as disabling as some of the problems 
caused by the disease itself.  
 A number of studies have been undertaken to evaluate the effects of dopamine agonists 
(ropinirole74,75 and pramipexole76,77) relative to L-dopa. All these studies suggest that 
compared with L-dopa, dopamine agonists may delay dyskinesia and showed less 
15 
 
dopamine neuron degeneration, although the value of this clinical effect remains uncertain 
and these agents do not improve total disability (using the unified Parkinson's disease rating 
scale (UPDRS) score1) compared with L-dopa. 
In the attempt to delay the development of motor fluctuations, many providers are now 
treating individuals with PD on a dopamine agonist rather than L-dopa. A dopamine agonist 
may be used until it no longer adequately relieves symptoms, at which point the person starts 
taking L-dopa in addition to the dopamine agonist. Dopamine agonists can also cause severe 
sleep problems and hallucinations in some people. Having these side effects may be another 
reason to switch to L-dopa. As long as the individual's symptoms are adequately controlled 
and they can tolerate the medicine, dopamine agonists may be a good choice for treating 
early PD. The American Academy of Neurology now recommends this course of treatment for 
most people with early PD, regardless of their age [www.aan.com/Guidelines]. 
When considering symptomatic drug therapy for both early and complex PD, the NICE 
guideline can best be described as ‘permissive’. The relative lack of comparative evidence 
between different classes of medicines precludes a ﬁrm recommendation for any one 
therapeutic strategy. Hence the guideline states that L-dopa, dopamine agonists and 
monamine oxidase type B (MAOB) inhibitors (see below) ‘may’ be used as a symptomatic 
treatment for early PD. ref 
3.2.3. MONOAMINE OXIDASE TYPE-B (MAO-B) INHIBITORS 
Recently, several studies have investigated the potential benefit of early treatment with 
MAO-B inhibitors such as seleginline80, and rasagiline.81,83,84 In 2004, a meta-analysis 
evaluating MAO-B inhibitors in patients with early PD found no difference in mortality among 
treatment versus control subjects.79 Patients randomized to MAO-B inhibitor therapy had 
significantly improved total UPDRS scores, as well as subdomain UPDRS motor scores and 
activities of daily living scores at 3 months. The MAO-B inhibitors were also well tolerated, 
with adverse effects and patient withdrawals from the study similar in both groups. These 
results illustrated a potential benefit of MAO-B inhibitors, which reduce degeneration of 
neurons. MAO-B inhibitors can be considered for initial treatment of early disease. These 
drugs provide mild symptomatic benefit, have excellent adverse effect profiles, and, 
according to a Cochrane review, have improved long-term outcomes in quality-of-life 
indicators by 20-25%.86 More details on the MAO-B inhibitors trials are reported in the table. 
  
                                                 
a The unified Parkinson's disease rating scale (UPDRS) is used to follow the longitudinal course of PD. It is made 
up of the 1) Mentation, Behavior, and Mood, 2) ADL and 3) Motor sections. These are evaluated by interview. 
Some sections require multiple grades assigned to each extremity. A total of 199 points are possible. 199 
represents the worst (total) disability), 0--no disability. 
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3.2.4. NONPHARMACOLOGICAL THERAPIES 
Since 2013, a number of studies have enhanced the literature and have guided clinicians on 
successful treatment interventions outside of pharmacotherapy and surgery. Thirty-three 
randomized controlled trials and one large observational study on exercise and physiotherapy 
were published in this period. Four randomized controlled trials focused on dance 
interventions, eight on treatment of cognition and behaviour, two on occupational therapy, 
and two on speech and language therapy (the latter two specifically addressed dysphagia). 
Three randomized controlled trials focused on multidisciplinary care models, one study on 
telemedicine, and four studies on alternative interventions, including music therapy and 
mindfulness.87 For example neuro-rehabilitation, including behavioural adaptations, can play 
an important role in the management of PD, by helping patients to deal with the decline in 
functioning while optimizing participation and quality of life. Its focus is on the patient as a 
person; the goals usually relate not only to disease symptoms, but also to social functioning 
and well-being.88 
However, the scientiﬁc evidence on its effectiveness is increasing87,89, and neuro-
rehabilitation is increasingly being integrated in the multidisciplinary care pathways for 
patients with PD.90 Many professional disciplines are involved in neuro-rehabilitation, 
including e.g. physiotherapists, occupational therapists and speech-language therapists; all 
these professionals need to integrate their own speciﬁc treatment contribution with each 
other, and align this with medical management. 
3.2.5. MULTIDISCIPLINARY DISEASE MANAGEMENT STRATEGIES 
A multidisciplinary approach combining pharmacological treatment with non-
pharmacological interventions to manage a complex disorder such as Parkinson's disease 
might be beneficial.91 Despite the shortage of evidence for effectiveness92, guidelines 
recommend regular access to a broad range of medical and allied health-care professionals93. 
Indeed, many centres deliver integrated and multidisciplinary care for patients with 
Parkinson's disease.94 However, a standard template for multidisciplinary care in Parkinson's 
disease does not exist, and guidelines do not clarify how a team approach should be organised 
and structured. 
The IMPACT trial{van der Marck, 2013 #193} assessed the effectiveness of an integrated 
multidisciplinary approach compared with usual care. This integrated care approach offered 
only small benefits to patients with Parkinson's disease, and these disappeared after 
correction for baseline disease severity. These results and those of previous studies support 
further development of well-designed clinical trials to obtain more knowledge and scientific 
evidence on how to organise team-oriented care in Parkinson's disease. 
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3.3. THE ECONOMIC BENEFITS OF EARLY INTERVENTION 
3.3.1. COST OF ILLNESS STUDIES 
Early intervention is likely to have a significant impact on costs for the healthcare sectors but 
also society overall; a number of cost of illness studies have found that the great majority of 
costs associated with PD occur in the later stages of the disease, when symptoms are at their 
most severe and, consequently, there is more need for healthcare service or caregivers 
support. Motor complications (motor fluctuations, dyskinesias, dystonia as uncontrollable 
and sometimes painful muscle spasms) have been identified as factors increasing PD-related 
costs 95-106. In all these studies severity of the disease was measured using the Hoehn and Yahr 
(HY) stage of PD (measured between 1, minimal disability, and 5, confinement to 
bed/wheelchair user)2.   
 In UK (2007) - Findley and colleagues96 found that the total cost in the UK lies between 
£449 million and £3.3 billion [€621 million and €4.6 billion] annually, depending on 
the cost model and prevalence rate used. The rise in social services costs was 
particularly influenced by the severity of the disease and reached approximately 
£7,000 [€9,700] per patient per year at stage 5. Increasing HY stage was also 
associated with an increasing proportion of secondary care within NHS costs (27% in 
stages 0–1, 62% in stage 5). The study identified that disease severity was the single 
most important cost driver: patients at HY stage 5 had costs that were six times higher 
than patients at stage 0 or 1 (£2971 vs £18,358; €4,113 vs. € 25,418 per patient per 
year). A key factor in this difference was the cost of institutional care. Among 
participants in the study who received institutional care, costs were more than 4.5 
times higher than for patients who remained at home. The financial burden of 
institutional care fell either on social services or on the patients themselves if they 
chose private care. Interestingly, medicine costs did not change with increasing 
disease severity and consequently they accounted for a lower proportion of the direct 
cost of PD in more severe cases. This study clearly shows how PD costs increase with 
the progression of the disease.  
 
 In UK (2003) - In another study McCrone and colleagues97 measured service use and 
costs for PD patients in the UK. The annual costs were £13,804 [€16,492] per patient. 
Formal care costs accounted for 20% of this amount, while informal care was related 
to 80% of the burden. Predictors of higher costs were identified, with male gender, 
level of disability and depression being the more significant ones. 
 
                                                 
2 The Hoehn and Yahr scale is a commonly used system for describing how the symptoms of Parkinson's disease 
progress. It was originally published in 1967 in the journal Neurology by Melvin Yahr and Margaret Hoehn and 
included stages 1 (Unilateral involvement only usually with minimal or no functional disability) through 5 
(Confinement to bed or wheelchair unless aided). 
18 
 
 In UK (2007) - A 2007 study developed in the UK98 showed that Levodopa induced 
dyskinesia increased health care costs. Relationship between increasing cost of care 
and severity of the disease was proven to be statistically significant. A correlation was 
also found between the severity of the disease, patient’s age and the use of Social 
Services. 
 
 In Italy (2003) - A study published in 200399 assessed health care costs associated with 
PD in Italy. Annual direct health costs were €4,320 for mild stage (HY 1-2), €4,748 for 
moderate stage (YH 2.5-3) and €6,175 for severe stage (HY 4-5). The average was 
estimated at €4,808. These results were identified as lower than the real cost, as they 
didn’t consider the societal perspective and neither informal care nor health care costs 
incurred in the private sector were included. 
 
 In Finland (2003) – In Finland the total annual cost-of-illness for PD outpatients was 
USD 131 million [EUR 118 million], including direct costs of USD 54.7 million [EUR 49.2 
million]. Keranen and colleagues100 found a significant association between PD 
severity and annual costs. Total costs in HY stages 1 to 2.5 were comparable, whereas 
they doubled in stage 3 and again in stage 4. In early stages of PD, direct costs 
accounted for most of the economic burden of the disease. However, for patients with 
more advanced PD, with HY stages 3.0–4.0, indirect costs accounted for increasing 
amounts of the economic burden, accounting for as much as half of the total costs in 
HY stage 4.0.100  
 
 In Germany (2000 and 2004) – Similarly in a German study101 it was found that disease 
severity (i.e. HY stage) alongside with motor complications and age, affected the costs 
of PD. The resource utilization in two cohorts of PD patients recruited in 2000 (n=145) 
and 2004 (n=133) were compared. Direct and indirect costs were assessed based on a 
patient diary and structured personal interviews. In 2004, total annual costs for PD 
ranged from €18,660 for HY (1 to 2) to €31,660 for HY (2 to 5). As compared to costs 
in 2000, total costs increased in 2004 by 25-31%.  
 
 In Germany (2004–2006) – In a subsequent German study102, the total costs per 
patient were €20,860 per PD patient; they increased according to HY disease stage 
severity, from average cost of €3,400 for HY stage 1 to €15,000 for HY stage 5, with 
the majority of costs originating from outside the formal healthcare system. When 
analysing the costs by HY stage, in contrast to the findings of the Finnish study, indirect 
costs remained stable over the course of the disease, but the direct costs in the 
advanced disease stages increase disproportionately.  
 
 In Spain (2012) - Matinez-Martin and colleagues103 estimated the magnitude in which 
PD symptoms and health-related QoL determined PD costs over a 4-year period. Mean 
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(SD) PD total costs increased about 92%, from €2,082.17 (€ 2,889) in year 1 to € 
4,008.6 (€7,757) in year 4. Total, direct and indirect cost increased 46%, 35%, and 70%, 
respectively, for mild disease (HY 1-3), whereas increases of 166% for total, 56% for 
direct and 348% for indirect costs in patients with moderate PD (HY 4) was observed. 
For severe patients (HY 5), cost remained almost the same throughout the study.  
 
 In Russia (2008). Costs of PD illness were studied also in Russia within a cohort of 100 
patients.104 From the societal perspective, total annual costs per patient amounted to 
€5,240 per patient, with direct costs accounting for 67% and indirect costs for 33% of 
the total. The main drivers of the burden were informal care and drugs. Global costs 
for the nation were estimated at €1.1 billion per year. 
 
 In Czech Republic (2010). A more recent study105 was performed in a cohort of 100 
Czech patients with idiopathic PD to evaluate direct and indirect costs and to identify 
cost-driving factors. Results were assessed for a 6-month period and have been 
projected to annual costs. Total annual costs for PD were €11,020 per patient. Direct 
costs accounted for 60% of the total costs and indirect for 40%. Independent cost 
driving factors included disease severity, motor complications, psychosis and age. 
 
 In a 6-month international observational study of PD in France, Germany and the 
UK106, patients with different degrees of motor complications, measured using the 
Unified Parkinson Disease Rating Scale (UPDRS), and its effects on health care costs 
were examined. Dyskinesia was associated with significant increases in total health 
care costs. Each unit increase in dyskinesia score lead to €562 additional costs per 
patient over a 6-month period. 
The economic evidence gathered in the literature shows that any strategy that would 
maintain PD symptoms in the earlier stages of the disease (when they are fewer and less 
severe) would likely prove substantially beneficial toward limiting expenditures. It is, 
therefore, possible that therapeutic interventions offered to patients before significant 
deterioration has occurred, when the potential for preserving neurophysiologic structures is 
maximized, may offer long-term cost savings. Indeed, little evidence points to the likelihood 
of short-term savings with early therapeutic intervention (although little evidence in this area 
exists in general), but long-term cost savings are entirely credible based on the delay of L-
dopa therapy and of the motor symptoms that require more intensive therapeutic 
interventions.45 
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3.3.2. COST-EFFECTIVENESS STUDIES  
 
A number of cost-effectiveness studies have also been undertaken to determine the 
economic value of early intervention for PD, and the results have been largely, if not 
unanimously, positive.  
 
 Dopamine agonist or MAO-B inhibitor (compared with L-dopa; UK 2009) 107- A study 
in the UK found that early treatment was cost-effective when patients with PD were 
treated with a dopamine agonist or MAO-B inhibitor (from a United Kingdom payer 
perspective). Early treatment delayed onset of dyskinesia and L-dopa initiation, and 
were associated with cost savings over a 5-year study period. More specifically, in this 
Markov model economic evaluation, data from 2 trials of dopamine agonists 
(rasagiline, pramipexole) in early PD were examined for effectiveness (time to L-dopa 
and time to L-dopa-induced dyskinesia), cost, and quality-adjusted life-years (QALYs). 
Rasagiline was found to reduce costs by 18% per patient over 5 years and 
demonstrated a 25% prolongation of time to L-dopa and a 10% delay in onset of 
dyskinesia. Rasagiline also demonstrated a 5% gain in QALYs relative to pramipexole. 
 
 Dopamine agonist (compared with L-dopa; USA 2005) 108- Another cost effectiveness 
study conducted from a US societal perspective found that treatment with 
pramipexole in patients with early PD was more cost effective and was associated with 
cost savings versus L-dopa in patients with depression and low baseline QoL. Under 
the base-case assumptions, the ICER for pramipexole was 42,989 US$ per QALY 
[€33,178 per QALY]. The probability that pramipexole was cost effective relative to L-
dopa over the first 4 years was 0.57, 0.77 and 0.82 when a QALY was valued at 50,000 
US$ [€38,589], 100,000 US$ [€77,178], and 150,000 US$ [€115,767], respectively. 
Over time, the ICER for pramipexole improved and uncertainty around the ICER 
decreased. If, after treatment withdrawal, QoL improved in pramipexole subjects and 
declined in L-dopa subjects (best-case scenario for pramipexole), the probability of 
pramipexole being cost effective increased to 0.88, 0.96 and 0.98, respectively. 
Factors that improved the ICER of pramipexole were a decrease in the relative price 
of pramipexole and having low QoL or depression at baseline. 
 
 Dopamine agonist (compared with baseline treatment patterns; USA 1998) 109- In an 
older study, Hoerger et al also found that pramipexole was cost-effective compared 
with baseline treatment despite initially higher medicine costs, especially in patients 
with early PD. For patients with advanced PD, the ICER was US$12,294/QALY, whereas 
for patients with early onset of PD, the ICER for pramipexole was US$8,837/QALY.  
 
All these economic analyses demonstrate that treatments other than L-dopa, especially when 
initiated early, may be cost-effective. However, despite this apparent benefit of utilizing 
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dopamine agonists in early PD to delay the need for L-dopa and to achieve cost savings, there 
is still controversy regarding when to initiate treatment. These studies referred to early 
treatment in the sense of the disease being treated soon after standard PD diagnosis has been 
achieved.45 If early PD is defined as that period prior to the onset of significant motor 
symptoms, then, as already considered with clinical outcomes, few data are available on the 
real potential for cost savings.  
 
 
3.4. THE BENEFITS OF TREATMENT ADHERENCE 
3.4.1. THE CLINICAL BENEFITS 
Patients with PD should take their medication as prescribed for numerous reasons.  
Firstly, sudden withdrawal of dopaminergic drugs can result in suppression of central 
dopamine transmission and thus trigger the neuroleptic malignant syndrome, which may lead 
to fatality.110  
Secondly, sporadic dopamine levels in blood plasma, partly from inadequate timing of 
medication taking, correlate with alternating high and low levels in the brain. Such erratic 
stimulation (the so called peak and trough effect) is proposed to result in motor fluctuations. 
Researchers evaluating the effect of reduced pill intake in PD showed that non adherence was 
associated with the ‘wearing off’ of the treatment effect.111 This was shown to result in motor 
fluctuations and increased risk of worsening symptoms compared to medication adherent 
individuals. Furthermore, poor adherence to treatment was associated with more unplanned 
hospital admissions for PD related problems and an overall poorer prognosis. 
Interestingly, and perhaps unique to PD, non-adherence to medication is not specific to sub-
optimal pill intake. Patients may also non-adhere by over medicating. Excessive intake of 
dopaminergic agents was prevalent in 10% of patients diagnosed with PD at a younger age.39 
The consequences of over medicating can be substantial and include severe medication 
induced dyskinesia, behavioural disturbances and potentially even psychosis.112,113 
Medication non-adherence in PD also has serious consequences for other parties involved.  
From the perspective of family members, their relative’s health is likely to deteriorate leading 
to poor QoL and increasing care requirements. This can place significant burden on the 
spouse/carer which can greatly affect their health and QoL. For treating clinicians, future 
management decisions are based on the premise that the patient is correctly taking the 
intended treatments. Dose escalation, adjunctive therapy use and, in some cases, diagnostic 
reconsideration may all be consequences of poor adherence.114 115 
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3.4.2. THE ECONOMIC BENEFITS 
Several USA-based studies reported that treatment adherence may have an impact on direct 
costs.  
 Davis et al (2010) employing insurance claims data from 30 managed care plans (using 
the Integrated Health Care Information Services Database), estimated that 61% of PD 
patients were non adherent to therapy over a 12-month period.48 Mean medical costs 
were significantly higher among non-adherent versus adherent subjects (US$15,826 
vs US$9,228 [€11,885 vs. €6,930]; P <0.01) despite the former having significantly 
lower prescription medicine costs (US$2,684 vs US$3,854 [€2,015 vs. €2,894]; P 
<0.05).  
 
 These data are consistent with results from another study in the USA (2011) showing 
that patients who were satisfactorily adherent to L-dopa/carbidopa/entacapone 
therapy had 39% fewer PD-related hospitalizations, 9% greater PD-related 
prescriptions, 47% lower inpatient costs, and 18% lower total costs than patients with 
unsatisfactory adherence. Overall all-cause total costs were US$3,508 [€2,360] less for 
those with satisfactory versus unsatisfactory adherence.116  
 
 Data from a national database of managed care plans (2010) found that non-adherer 
patients had significantly higher rates of yearly hospitalizations, healthcare visits, and 
higher total medical costs (US$15,826 vs. US$9,228; €11,885 vs. €6930) despite lower 
prescription medicine costs. Overall non-adherence was associated with a US$3,451 
[€2,591] yearly increase in medical costs.117  
 
 More data from the USA (2013)118 showed that, although total drug mean costs were 
higher for compliant patients than non-compliant patients (driven mainly by the cost 
of PD-related medications), the mean costs associated with emergency room and 
inpatient visits were higher for patients non-compliant with their prescribed 
medication. Overall, the total all-cause annual healthcare mean cost was lower for 
compliant than for non-compliant patients (US$77,499 vs. US$84,949; €59,286 vs. 
€64,985). 
 
3.4.3. NEW INTERVENTIONS TO SUPPORT ADHERENCE 
A Cochrane review of interventions for enhancing medication adherence across numerous 
medical conditions found only a small number to have a statistically significant impact on 
short- and long-term adherence, with improvement in treatment outcomes even less 
common. Of the successful interventions, most were complex combinations of increased 
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follow-up, regimen simplification, mailed and telephoned reminders or reinforcement, 
counselling, and supportive care.119  
 
For example, a study in the UK (2007) compared targeted verbal and written patient 
education on the continuous dopaminergic theory to usual care. Electronic medication 
monitoring devices assessed adherence to medication timing before and after the 
educational intervention.120 At baseline, only 17–21% of all medications were taken at the 
appropriate time interval, with a statistically significant increase to 39% of all doses in the 
active group post-intervention. There were no statistically significant differences between 
QoL, UPDRS scores, or adverse events between groups. The study was limited by short follow-
up and substantial attrition in both groups. A second study is evaluating a brief form of 
cognitive-behavioural therapy focused on medication adherence in patients and caregivers 
with PD.121 This study, too, is limited by a short duration of planned follow-up, and the 
assessment of medication adherence by a surrogate marker rather than a gold standard. 
 
Further research is necessary to explore the patient characteristics, beliefs, and decision-
making processes associated with medication non-adherence. These investigations should 
include for example electronic medication monitoring caps (medication monitoring systems 
that track medication usage without active input from the patient)114 and account for the 
frequent involvement of family and caregivers in PD management. 
It is also important to consider the complexity of PD, and the fact that it is a chronic disease 
with a spectrum of manifestations that appear and change as the disease progresses. 
Consequently, treatment efficacy and patient well-being are improved when a 
multidisciplinary disease management approach to PD is implemented and specialists (i.e. 
neurologists) are part of the management team alongside other healthcare professionals as 
appropriate.122 By employing a multidisciplinary disease-management strategy, healthcare 
professionals with expertise in PD can provide informed guidance with regard to the selection 
of treatments that are likely to be most effective and to which patients are most likely to be 
adherent.  
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4. KEY MESSAGES FROM THE LITERATURE 
The literature confirms that early diagnosis and treatment of PD are paramount to: reducing 
the risk of disease progression; limiting the effects of PD on QoL; and potentially lowering 
long-term treatment costs.  
Standard current approaches to PD diagnosis rely on the presence of motor symptoms; 
therefore the diagnosis is mainly clinical, and may occur at later stage of the disease, when 
significant irreversible neurological damage may have already occurred and there is no 
opportunity to delay disease progression.  
However, the combination of a new definition of PD (to include early pre-motor symptoms) 
and new diagnostic tools may allow for early diagnosis, and therefore treatment of the 
disease. Biologic biomarkers offer some of the most useful tools for reliable early PD 
diagnosis. In addition, neuroimaging techniques, particularly SPECT and MRS, also show 
enormous potential because of their high degrees of sensitivity and specificity in diagnosing 
early PD. However a widespread use of such screening strategies may be limited by practical 
constraints due to the limited availability of the medical technologies and their high costs. 
Any cost savings resulting from an early diagnosis achieved through the implementation of 
better neuroimaging techniques should take into account the implementation cost.  
Patient’s treatment adherence has also been identified as a key area which is able to impact 
clinical outcomes and costs. Finally, a disease-management strategy through the 
implementation of a chronic model of care, is important to improve treatment adherence and 
rates of correct diagnosis. Clinicians should be informed regarding proper diagnostic 
approaches, ensuring diagnosis is performed by those clinicians with appropriate skill sets, 
and availing them of emerging techniques for early and accurate diagnosis.  
It is important that healthcare managers  and policy makers recognise the changes taking 
place in the detection and treatment of PD, and take advantage of opportunities for the 
earliest possible intervention in PD before major neurological damage occurs and treatment 
may become less effective and more expensive.45 
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5. WHAT HAS NOT BEEN ADDRESSED SO FAR AND SHOULD BE 
CONSIDERED IN FUTURE RESEARCH? 
5.1. RETHINKING WHAT PD IS AND HOW/WHEN IT CAN BE DIAGNOSED 
The recent developments in PD diagnosis emphasise the necessity of rethinking what PD is 
and how, and when, it can be diagnosed. Clinicians are aware that the current diagnostic tools 
and guidance should be updated in light of current knowledge of PD to optimize its early 
detection. Critical issues to be solved with regard to the current PD definition includes:  
 Who decides what PD is and what is the gold standard for a “final” diagnosis? What 
clinical features fit under the definition of PD and should be incorporated into the 
diagnosis? With regard to defining disease onset, can PD be defined before classic 
motor features develop? Are new diagnostic tools needed to fit the new definition 
of PD?  
In recognition of the profound changes in the understanding of PD, the International 
Parkinson and Movement Disorders Society (MDS) has recently commissioned a task force 
to discuss these critical issues and to consider a redefinition of PD.123 More research is 
needed to further explore these key areas which should be informed by solid real-world 
evidence rather than by limited clinical practice. 
 How do we define early PD? Despite the evidence of the beneficial effects of early 
diagnosis and treatment, all the studies found in the literature define early PD only in 
the sense of the disease being treated soon after standard PD diagnosis has been 
achieved, i.e. after the presence of motor symptoms (when around 70% of all 
dopamine neurons may have been lost).45  
 
If, however, early PD is defined as that period prior to the onset of significant motor 
symptoms, before substantial neurological damage may have occurred, then limited data is 
available that describes the real potential of early treatment in terms of clinical and economic 
outcomes. Thus, more research would be needed to explore the real impact of early 
treatment both on clinical and economic outcomes.  
Furthermore, with the advent of new diagnostic tools, such as genetic biomarkers, 
forthcoming studies should assess the impact of these medical innovations in terms of clinical 
and economic outcomes.  
5.2. DO WE HAVE PREFERRED TREATMENT OPTIONS? 
 
Although the literature seems to confirm that early treatment is beneficial, there is still 
debate regarding whether treatment (with L-dopa which is limited by eventual wearing-off 
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effects) should be initiated immediately or delayed until greater motor functional disability 
presents.124 In addition to the wearing-off effect, there is also some risk of additional side 
effects involved with starting treatment early. Certain medicines commonly used in PD 
including L-dopa, anticholinergic agents, and dopamine agonists are associated with different 
side effects (e.g hypotension, arrhythmia, insomnia, hallucinations) that can have a negative 
impact on patient’ QoL and therapeutic adherence. Nonetheless, early treatment of PD might 
bring important benefits, such as potentially enhancing the effects of mechanisms that 
compensate for the deficits caused by PD. What is still unclear is whether early treatment can 
bring neuroprotection or whether outcome modification can be achieved. Also being 
questioned is the effect of early initiation of a therapy other than L-dopa on disease 
progression.72 The benefits of alternative medicine formulations, regimen simplification, or 
non-pharmacological interventions (for examples see neuro-rehabilitation89, the 
introduction of ICT [information and communications technology] wearable sensors125  and 
integrated care models126) should be further explored as these may present opportunities to 
improve outcomes and lower costs in PD.  
Considering health systems reforms taking place all over Europe and the challenges related 
to the management of chronic conditions, including co-morbidities and ageing, new models 
of care that include a societal benefits approach need to be examined to ensure more 
coordinated and integrated care. The EBC Value of Treatment project for 2015-2017127 aims 
at developing and applying to brain disorders a new integrated care model framework and 
therefore promote a more holistic management of chronic conditions in Europe. The project 
will provide evidence on how to implement effective and cost-effective interventions across 
a series of brain disorders, including Parkinson’s disease.  
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7. LIST OF ABBREVIATIONS 
Alzheimer’s disease (AD) 
Central nervous system (CNS) 
Cerebrospinal fluid (CSF) 
Corticobasal degeneration (CBD) 
Dementia with Lewy bodies (DLB) 
Essential tremor (ET) 
European Brain Council (EBC) 
Hoehn and Yahr (HY)   
Idiopatic parkinson’s disease (IPD)   
Incremental cost effectiveness ratio (ICER)   
Information and communications technology (ICT) 
Levodopa (L-dopa) 
L-dopa/carbidopa/entacapone (LCE) 
L-dopa/carbidopa (LC) 
Magnetic resonance imaging (MRI) 
Magnetic resonance spectroscopy (MRS) 
Managed care organizations (MCOs)   
Monoamine Oxidase Type-B (MAO-B)  
Multiple system atrophy (MSA) 
Multisystem atrophy (MSA) 
Non-motor symptoms scale (NMSS)   
Normal pressure hydrocephalus (NPH) 
Parkinson’s disease (PD) 
Peripheral nervous system (PNS) 
Physical therapy (PT)   
Positron emission tomography (PET) 
Progressive supranuclear palsy (PSP) 
Quality-adjusted life-years (QALYs)   
Quality of life (QoL) 
Single photon emission computed tomography (SPECT) 
Transcranial sonography (TCS) 
Unified Parkinson's disease rating scale (UPDRS) 
 
